Reviewer’s report

Title: Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer

Version: 1 Date: 30 July 2013

Reviewer: Sybille Mazurek

Reviewer’s report:

There are only two minor points which should be clarified before publication (minor essential revisions):

1. In the abstract the authors write that 57 patients met the eligibility criteria. In the methods section and Figure 1 the study population consists of 56 patients.

2. In the result section on page 10 first line the authors write that 18 patients had a tumor PKM2 mRNA expression of less than 0.70.

The authors should indicate what they mean by “tumorPKM2”. In some papers tumor PKM2 is the abbreviation of the dimeric form of PKM2.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I was invited from the Karolinska Institute for a lecture for two times and received reimbursement of travel and accommodation costs.

I was employee of the ScheBo Biotech AG, the company which developed the M2-PK plasma and stool test for CRC screening and follow up studies until June 2012.